
The pharmaceutical giant sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it currently sells for myasthenia gravis.

The pharmaceutical giant sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it currently sells for myasthenia gravis.